Von Willebrand Factor Expression in a Shiga Toxin-mediated Primate Model of Hemolytic Uremic Syndrome
- 1 September 2002
- journal article
- Published by SAGE Publications in Pediatric and Developmental Pathology
- Vol. 5 (5) , 472-479
- https://doi.org/10.1007/s10024-001-0204-1
Abstract
Von Willebrand Factor (vWF) is stored and released from activated or damaged endothelial cells and platelets, and its multimers have considerable prothrombotic properties. To investigate the role of vWF in the pathogenesis of post-diarrheal (D+) hemolytic uremic syndrome (HUS), we used a baboon model to study vWF expression following the intravenous administration of 100 ng/kg of Shiga toxin 1 (Stx 1), given either as a single dose, or as four divided doses, with and without lipopolysaccharide (LPS). vWF antigen was measured in plasma and urine obtained at 0, 12, 24, 36, 48, and 60 h by enzyme-linked immunosorbent assay (ELISA), and immunohistochemical expression of vWF in renal tissue obtained at autopsy was quantified by image analysis. Animals that received the single dose of Stx 1, or the four divided doses of Stx 1 plus LPS uniformly developed HUS, but those that received divided doses of Stx 1 without LPS, or LPS alone did not. Plasma vWF levels rose significantly in animals that received LPS, with or without Stx 1; but not in those that received Stx 1 alone. Urine vWF levels were generally undetectable. vWF expression was greater in renal tissue of animals that developed HUS than in those that did not, and was seen in both glomeruli, and, especially, peritubular capillaries. Since HUS developed in animals that did not experience a rise in plasma vWF levels, it does not appear that LPS-mediated systemic vWF release is essential to the pathogenesis of HUS in our model. The renal tissue findings, however, suggest a role for Stx-mediated intrarenal vWF release in the acute nephropathy of D+ HUS.Keywords
This publication has 21 references indexed in Scilit:
- The Role of Virulence Factors in Enterohemorrhagic Escherichia coli (EHEC) - Associated Hemolytic-Uremic SyndromeSeminars in Thrombosis and Hemostasis, 2001
- Von Willebrand Factor and Von Willebrand Factor-Cleaving Metalloprotease Activity in Escherichia coli O157:H7-Associated Hemolytic Uremic SyndromePediatric Research, 2001
- The United States National Prospective Hemolytic Uremic Syndrome Study: Microbiologic, Serologic, Clinical, and Epidemiologic FindingsThe Journal of Infectious Diseases, 2001
- Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndromeBlood, 2000
- Antibodies to von Willebrand Factor–Cleaving Protease in Acute Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 1998
- von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic SyndromeNew England Journal of Medicine, 1998
- Hemolytic-Uremic Syndrome in AdolescentsArchives of Pediatrics & Adolescent Medicine, 1997
- High incidence of serum antibodies to Escherichia coli O157 lipopolysaccharide in children with hemolytic-uremic syndromeThe Journal of Pediatrics, 1991
- Prognostic Markers in Diarrhoea-Associated Haemolytic-Uraemic Syndrome: Initial Neutrophil Count, Human Neutrophil Elastase and Von Willebrand Factor AntigenNephrology Dialysis Transplantation, 1991
- Globotriosyl ceramide is specifically recognized by the escherichia coli verocytotoxin 2Biochemical and Biophysical Research Communications, 1988